Análisis costo-beneficio de las estatinas (atorvastatina, pravastatina, simvastatina) en la prevención secundaria del infarto cerebral: Una revisión sistemática
Contenido principal del artículo
Resumen
Las enfermedades cerebrovasculares comprenden trastornos tan destructivos como los accidentes isquémicos o hemorrágicos y anomalías vasculares cerebrales y constituyen la 3a. causa de muerte y la principal causa de discapacidad. El uso de estatinas ofrece alternativas costo-efectivas para su tratamiento.
Detalles del artículo
Sección
Cómo citar
Referencias
Kasper D, et al. Harrison's Principles of Internal Medicine. 16th. Ed. McGraw-Hill; 2005, p. 1609-10.
Kirshner HS, Biller J, Callahan AS 3rd. Long-term therapy to prevent stroke. [Journal Article. Research Support, Non-U.S. Gov't] J Am Board of Family Practice 2005: 18(6): 528-40.
Somor R, Aminoff M, Greenberg D. Neurología clínica. 4a. Ed. México: Editorial Manual Moderno; 2001.
Cabrera A, Martinez O, et al. Epidemiología de la enfermedad vascular cerebral en hospitales de la Ciudad de México: estudio multicéntrico. Med Int Mex 2008; 24(2): 98-103.
Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47: 1255-6.
Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-6.
Di Napoli M, Papa F, and Bocola V. C-Reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-24.
Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl. 3): 483S-512S.
Ezekowitz JA, Straus SE, Majumdar SR, et al. Stroke: strategies for primary prevention. Am Fam Physician 2003; 68: 2379-86.
Kirshner HS. Medical prevention of stroke. South Med J 2003; 96: 354-8.
Strauss S, Majumdar SR, McAlister FA. New evidence for stroke prevention. JAMA 2002; 288: 1388-95.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
Schwertz DW, Badellino KO. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review. [Journal Article] J Cardiovas Nur 23(1): 2008; 8-13.
Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003; 163: 669-76.
Rosenson RS. Biological basis for statin therapy in stroke prevention.[erratum appears in Curr Opin Neurol 2000 Jun;13(3):365]. [Review] [68 refs] [Journal Article. Review] Current Opinion in Neurology 2000; 13(1): 57-62.
Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. [Review] [Comparative Study. Journal Article. MetaAnalysis. Research Support, Non-U.S. Gov't. Review] BMC Family Practice 2003; 4: 18.